Jim Wilson biotech iECURE gets fresh $65M to push pediatric liver disease gene therapy into the clinic

Lei Lei Wu

News Reporter

Jim Wilson-founded biotech iECURE has wrapped a $65M Series A extension round to get its lead candidate — a gene replacement therapy for a rare inherited …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Jim Wilson biotech iECURE gets fresh $65M to push pediatric liver disease gene therapy into the clinic

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Jim Wil­son biotech iECURE gets fresh $65M to push pe­di­atric liv­er dis­ease gene ther­a­py in­to the clin­ic

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Jim Wilson biotech iECURE gets fresh $65M to push pediatric liver disease gene therapy into the clinic